Q-omics provides the consensus-scored C16orf92 profile across patient tissues and cancer cell-line models. C16orf92 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C16orf92 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, C16orf92 RNA expression shows 11,718 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight HNSC, BRCA, and PCPG as cancer lineages where C16orf92 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C16orf92 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C16orf92 survival associations across molecular data types. C16orf92 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C16orf92 RNA expression–survival associations across cancer types. High C16orf92 expression shows unfavorable associations in MESO, COAD and KIRP, but favorable associations in HNSC, PAAD and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for C16orf92 RNA expression.
This table summarizes C16orf92 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for C16orf92. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C16orf92 shows higher tumor expression in BRCA, LIHC, ESCA, LUSC, LUAD and THCA. The BRCA box plot shows higher C16orf92 RNA expression in tumor versus normal tissue (log2 FC = +0.201, t-test p < 0.001).
This table shows molecular features associated with C16orf92 in patient tissues and cancer cell lines. In patient samples, C16orf92 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, C16orf92 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
